English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: IMP3, PPARG and PD-L1 have been implicated in tumorigenesis and progression in many cancers, but their significance in urothelial carcinoma remains unclear. Aim: The aim of this study is to assess the possible significance of IMP3, PPARG and PD-L1 in urothelial bladder carcinoma and determine the relation between their expressions and different clinicopathological (tumor size, grade, histological variant, muscle invasion, lymphovascular invasion and pathologic T stage) and molecular variables. Methods: This study aimed to evaluate immunohistochemical expression of IMP3, PPARG and PD-L1 and correlate them with clinicopathological and molecular variables. Results: IMP3 was significantly correlated to muscle invasion (P<0.01), tumor grade (P<0.05), histological variant (P<0.05), lymphovascular invasion (P<0.01) and PT stage (P<0.01). PPARG was inversely correlated to muscle invasion (P<0.01), tumor grade (P<0.01), histological variant (P<0.01), PT stage (P<0.05) and molecular subtype (P<0.01). PD-L1 was significantly correlated to muscle invasion (P<0.05), histological variant (P<0.05) and PT stage (P<0.01). IMP3 and PD-L1 showed high statistically significant correlation (P<0.01). IMP3 and PPARG showed inverse statistically significant correlation (P<0.05). No significant correlation between PPARG and PD-L1expression was detected (P>0.05).Conclusions: IMP3 may be used as a prognostic marker. PPARG may be used to identify the luminal molecular subtype. PD-L1 may be used as a prognostic marker for tumor aggressiveness, so it may be used in immunotherapy. Keyword: Urothelial carcinoma, IMP3, PPARG, PD-L1. a Department of pathology, Benha faculty of medicine, Benha University, Egypt. b Department of pathology Military Medical Academy, cairo, Egypt Correspondence to: Ebtehal AbdelAal, Department of pathology, Benha faculty of medicine, Benha University, Egypt.

Significance of Expression of IMP3, PPARG & PD-L1 in Urothelial Carcinoma (Immunohistochemical Study)